A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT’s) in multiple sclerosis (MS)

Archibald de Ceuninck van Capelle, Hanneke van der Meide, Frans J H Vosman and Leo H Visser

PLOS ONE, 2017, vol. 12, issue 8, 1-10

Abstract: Background: Physicians commonly advise patients to begin disease modifying therapies (DMT’s) shortly after the establishment of a diagnosis of Multiple Sclerosis (MS) to prevent further relapses and disease progression. However, little is known about the meaning for patients going through the process of the diagnosis of MS and of making decisions on DMT’s in early MS. Objective: To explore the patient perspective on using DMT’s for MS. Methods: Ten participants with a recent (

Date: 2017
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182806 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 82806&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0182806

DOI: 10.1371/journal.pone.0182806

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone (plosone@plos.org).